| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (NCT05267262) | River 3 Renal Corp. | 2022-06-15 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (NCT05441826) | Tenet Medicines | 2022-05-03 |
| NEPTUNE Match Study (NCT04571658) | University of Michigan | 2022-05-02 |
| Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (NCT05200871) | Travere Therapeutics, Inc. | 2022-02-05 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (NCT05003986) | Travere Therapeutics, Inc. | 2021-08-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases (NCT04573920) | Novartis Pharmaceuticals | 2021-03-15 |
| Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System (NCT04065438) | Kaneka Medical America LLC | 2020-01-01 |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease (NCT04009668) | University of Michigan | 2019-10-02 |
| PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant (NCT03763643) | University of Minnesota | 2019-07-01 |
| KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis (NCT03929887) | Seoul National University Hospital | 2019-05-01 |
| LDL-Apheresis for FSGS CardioRenal Outcomes (NCT04088799) | Children's Hospital Medical Center, Cincinnati | 2019-01-01 |
| Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (NCT03649152) | Dimerix Bioscience Pty Ltd | 2018-11-08 |
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome (NCT03703908) | Amgen | 2018-10-01 |
| Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome (NCT03298698) | Radboud University Medical Center | 2018-08-22 |
| Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (NCT03598036) | Aurinia Pharmaceuticals Inc. | 2018-06-21 |
| A Study of CCX140-B in Subjects With FSGS (NCT03536754) | Amgen | 2018-05-17 |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (NCT03493685) | Travere Therapeutics, Inc. | 2018-04-17 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX (NCT03366337) | Biogen | 2017-12-26 |
| Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis (NCT03126201) | Istanbul University | 2016-12-01 |
| Valproic Acid for Idiopathic Nephrotic Syndrome (NCT02896270) | Universitair Ziekenhuis Brussel | 2016-10-01 |
| Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) (NCT02592798) | Bristol-Myers Squibb | 2016-03-09 |
| Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (NCT02585804) | University Health Network, Toronto | 2015-09-01 |
| Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis (NCT02693366) | Universidade Federal do Rio de Janeiro | 2015-06-25 |
| Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children (NCT02235857) | Kaneka Medical America LLC | 2015-05-03 |
| Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) (NCT02382874) | Royan Institute | 2015-05-01 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (NCT01613118) | Travere Therapeutics, Inc. | 2014-03-01 |
| Regional Citrate Anticoagulation in Plasma Exchange Treatment (NCT01370200) | University Medical Centre Ljubljana | 2011-04-01 |
| National Registry of Rare Kidney Diseases (NCT06065852) | UK Kidney Association | 2009-11-06 |
| Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome (NCT01113385) | Children's National Research Institute | 2009-10-01 |
| Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis (NCT00956059) | Xi'an Jiaotong University | 2009-09-01 |
| Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (NCT01129557) | Columbia University | 2009-09-01 |
| Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 (NCT00816504) | Northwell Health | 2008-12-01 |
| Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor (NCT00816478) | Northwell Health | 2008-12-01 |
| Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (NCT00814255) | NYU Langone Health | 2008-12-01 |
| Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis (NCT00883636) | Northwell Health | 2008-10-01 |
| Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) (NCT00782561) | Kyntra Bio | 2008-04-01 |
| Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS (NCT00464321) | Genzyme, a Sanofi Company | 2007-05-01 |
| Kidney Disease Biomarkers (NCT00255398) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2005-11-10 |
| Permeability Factor in Focal Segmental Glomerulosclerosis (NCT00007475) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2000-12-01 |
| Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure (NCT02194582) | Beth Israel Deaconess Medical Center | 1996-06-01 |
| Genetic Markers for Focal Segmental Glomerulosclerosis (NCT00001393) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1996-04-15 |